Skip to main content
SpringerLink
Log in

26-jährige Therapiedauer

Lipoproteinapherese im Langzeitverlauf

  • Fortbildung
  • Lipidsprechstunde
  • Published:
CardioVasc Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Schettler V, Wieland E. [Effects of LDL-apheresis—more than reduction of cholesterol?]. Dtsch Med Wochenschr. 2007;132:575–8

    Article  CAS  Google Scholar 

  2. Fischer S, Julius U, Tselmin S et al. [Lipoprotein(a): a risk factor for atherosclerosis]. Dtsch Med Wochenschr. 2014;139:1204–6

    Article  CAS  Google Scholar 

  3. Jaeger BR, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6:229–39

    CAS  PubMed  Google Scholar 

  4. Leebmann J, Roeseler E, Julius U et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128:2567–76

    Article  CAS  Google Scholar 

  5. Mellwig KP, Baller D, Gleichmann U et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 1998;139:173–8

    Article  CAS  Google Scholar 

  6. Stefanutti C, Mazza F, Pasqualetti D et al. Lipoprotein apheresis downregulates IL-1alpha, IL-6 and TNF-alpha mRNA expression in severe dyslipidaemia. Atheroscler Suppl. 2017;30:200–8

    Article  Google Scholar 

  7. Leebmann J. Lipoproteinapherese — Wie sieht die Praxis aus? Dialyse Aktuell. 2013;17:535–9

    Google Scholar 

  8. Schettler VJJ, Neumann CL, Peter C et al. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on. Atheroscler Suppl. 2017;30:50–5

    Article  CAS  Google Scholar 

  9. Mabuchi H, Koizumi J, Shimizu M et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1998;82:1489–95

    Article  CAS  Google Scholar 

  10. Seidel D. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy]. Z Kardiol 2003;92(Suppl 3):iii6–27

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Herz- und Diabeteszentrum NRW, Klinik für Allgemeine und Interventionelle Kardiologie/Angiologie, Georgstr. 11, 32545, Bad Oeynhausen, Deutschland

    Klaus Peter Mellwig

Authors
  1. Klaus Peter Mellwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Peter Mellwig.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mellwig, K.P. Lipoproteinapherese im Langzeitverlauf. CV 19, 22–24 (2019). https://doi.org/10.1007/s15027-019-1509-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-019-1509-1

Search

Navigation